We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review
A pessimistic view of serologic markers for diagnosis and management of osteoarthritis. Biochemical, immunologic and clinicopathologic barriers.
Journal of Rheumatology. Supplement 1989 August
The diagnosis of osteoarthritis (OA) is usually based on clinical and radiologic findings and is usually made only after the patient presents with joint pain. There is today much interest in development of an immunologic "marker" of OA, to detect subclinical disease and/or monitor therapy. The approach employs measurement of serum or synovial fluid levels of articular cartilage macromolecules, such as proteoglycans or glycosaminoglycans, or fragments of these. The data, however, raise questions about interpretation and utility of such tests. What causes egress of such macromolecules from OA cartilage? Overproduction? Hypercatabolism? Leakage from an excessively permeable matrix? Does the marker reflect the rate of cartilage breakdown? Or of repair? How reliable are the quantitative immunologic methods in tests of sera from patients with OA? Data show, for example, that serum keratan sulfate levels may be influenced by the mode of presentation of the antigen, i.e., single vs multiple chains, and by the degree of sulfation, etc. To what extent might serum levels of a marker reflect release from degenerating but asymptomatic joints, rather than from painful joints? Also, since all putative marker molecules studied to date are widely distributed throughout the connective tissue of the body, they could be released from an asymptomatic degenerating intervertebral disc rather than, e.g., a painful osteoarthritic hip or knee. In the present climate of "marker mania," it should be emphasized that no marker exists today which can confidently be used for diagnosis of subclinical OA or for monitoring therapeutic response.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app